Our vision is to save human lives by transforming a natural substance into a breakthrough treatment for METASTATIC RENAL CANCER.

Read more

Are you or do you have possible candidates for our clinical trials?

We are looking for patients who suffer from metastatic renal cancer and would like to participate in a clinical trial to test a new potential treatment. The objective of the study is to evaluate the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients with Metastatic Clear-Cell or Papillary Renal Cell Carcinoma. Find out more about the trial and check your or your candidate’s eligibility here: 

Read more
Alternate Text

Urgent and major unmet medical need

Arrow

Oncorena breaks new ground in developing an innovative treatment for patients with metastatic renal cancer. About one-third of kidney cancer patients are diagnosed with this fatal disease and...

Building value based on clinical validation

Arrow

Responding to this challenge, Oncorena is developing a first-in-class treatment based on orellanine, a naturally occurring substance from the Cortinarius family of mushrooms...

Our research makes a difference

Arrow

Oncorena is developing a first-in-class therapy for metastatic renal cancer…

Latest News

Sofia Heigis News

Sofia Heigis Elected New Board Member of Oncorena

The Annual General Meeting of Oncorena Holding AB was held today, June 16, 2026, at Medicon Village, Scheeletorget 1, Lund, Sweden. The AGM resolved to elect Sofia Heigis as a new member…

Read more
ONCORENA Image Generated With Adobe Firefly

Oncorena receives regulatory approval in France and Portugal to initiate the Oncorella-1 clinical study

Oncorena is pleased to announce that French and Portuguese regulatory authorities have granted approval to expand th…

Read more
Oncorena Juni25 (2)

Oncorena’s new issue of shares fully subscribed

Oncorena communicates that the new issue of shares was fully subscribed to a sum of 133 million SEK (US$ 13.9M).

Read more
Oncorena FDA Nyhet

Oncorena receives FDA approval to initiate studies in the US

Oncorena is pleased to announce that the FDA has approved the Company’s IND application to initiate the Phase I/II s…

Read more

Quick Facts